Enhancement of invasion of hepatocellular carcinoma cells through lysophosphatidic acid receptor

Journal of International Medical Research

Volumn 41, Issue 1, 2013, Pages 55-63

  Lou, Lianqing ^a   Chen, Yong Xin ^a   Jin, Lingzhen ^a   Li, Xiaofei ^a   Tao, Xingfei ^a   Zhu, Jinhong ^a   Chen, Xiangyi ^a   Wu, Shuang ^a   Ye, Weiwei ^a   He, Jinke ^a   Ding, Guoqiang ^a  

^a YIWU CENTRAL HOSPITAL   (China)

Author keywords

Hepatocellular carcinoma (HCC); Invasion; Lysophosphatidic acid (LPA); Matrix metalloproteinase (MMP)

Indexed keywords

3 [4 [4 [[1 (2 CHLOROPHENYL)ETHOXY]CARBONYLAMINO] 3 METHYL 5 ISOXAZOLYL]BENZYLSULPHANYL]PROPANOIC ACID; GELATINASE A; GELATINASE B; KI 16425; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; LYSOPHOSPHATIDIC ACID RECEPTOR 2; LYSOPHOSPHATIDIC ACID RECEPTOR 3; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL ADHESION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE; GENE EXPRESSION; GENE FUNCTION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LPAR GENE; LPAR1 GENE; LPAR2 GENE; LPAR3 GENE; MMP2 GENE; MMP9 GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR INVASION; UPREGULATION;

EID: 84878419751     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060512474124     Document Type: Article

References (31)

1. Llovet JM, Burroughs A and Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
2. Poon RT, Fan ST, Ng IO, et al. Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg 2003; 237: 376-383.
3. Bartsch JE, Staren ED and Appert HE. Adhesion and migration of extracellular matrix-stimulated breast cancer. J Surg Res 2003; 110: 287-294.
4. Mareel M and Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 2003; 83: 337-376.
5. Moolenaar WH. Development of our current understanding of bioactive lysophospholipids. Ann NY Acad Sci 2000; 905: 1-10.
6. Toews ML, Ustinova EE and Schultz HD. Lysophosphatidic acid enhances contractility of isolated airway smooth muscle. J Appl Physiol 1997; 83: 1216-1222.
7. Mori M and Tsushima H. Activation of Rho signaling contributes to lysophosphatidic acid-induced contraction of intact ileal smooth muscle of guinea-pig. Can J Physiol Pharmacol 2000; 78: 729-736.
8. Jalink K, Eichholtz T, Postma FR, et al. Lysophosphatidic acid induces neuronal shape changes via a novel, receptor-mediated signaling pathway: similarity to thrombin action. Cell Growth Differ 1993; 4: 247-255.
9. Tigyi G, Fischer DJ, Sebok A, et al. Lysophosphatidic acid-induced neurite retraction in PC12 cells: control by phosphoinositide-Ca2{thorn} signaling and Rho. J Neurochem 1996; 66: 537-548.
10. Moolenaar WH, van Meeteren LA and Giepmans BN. The ins and outs of lysophosphatidic acid signaling. Bioessays 2004; 26: 870-881.
11. Anliker B and Chun J. Lysophospholipid G protein-coupled receptors. J Biol Chem 2004; 279: 20555-20558.
12. Mills GB and Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nature Rev 2003; 3: 582-591.
13. van Corven EJ, Groenink A, Jalink K, et al. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell 1989; 59: 45-54.
14. Moolenaar WH. Mitogenic action of lysophosphatidic acid. Adv Cancer Res 1991; 57: 87-102.
15. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007; 115: 84-105.
16. Noguchi K, Herr D, Mutoh T, et al. Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 2009; 9: 15-23.
17. Zhu B, Shi S, Ma YG, et al. Lysophosphatidic acid enhances human hepatocellular carcinoma cell migration, invasion and adhesion through P38 MAPK pathway. Hepatogastroenterology 2012; 59: 785-789.
18. Sun H, Ren J, Zhu Q, et al. Effects of lysophosphatidic acid on human colon cancer cells and its mechanisms of action. World J Gastroenterol 2009; 15: 4547-4555.
19. Folkman J. A new link in ovarian cancer angiogenesis: lysophosphatidic acid and vascular endothelial growth factor expression. J Nat Cancer Inst 2001; 93: 734-735.
20. McKenna GJ, Chen Y, Smith RM, et al. A role for matrix metalloproteinases and tumor host interaction in hepatocellular carcinomas. Am J Surg 2002; 183: 588-594.
21. Hidalgo M and Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Nat Cancer Inst 2001; 93: 178-193.
22. Hayasaka A, Suzuki N, Fujimoto N, et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/ gelatinase B) in hepatocellular carcinoma. Hepatology 1996; 24: 1058-1062.
23. Ohta H, Sato K, Murata N, et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 2003; 64: 994-1005.
24. Mineva I, Stamenova M, Gartner W, et al. Expression of the small heat shock protein alphaB-crystallin in term human placenta. Am J Reprod Immunol 2008; 60: 440-448.
25. Qin LX and Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 385-392.
26. Hosch SB, Steffani KD, Scheunemann P, et al. Micrometastases from HBP malignancies and metastatic cancer. J Hepatobiliary Pancreat Surg 2002; 9: 583-591.
27. Pua TL, Wang FQ and Fishman DA. Roles of LPA in ovarian cancer development and progression. Future Oncol 2009; 5: 1659-1673.
28. Jiang YF, Yang ZH and Hu JQ. Recurrence or metastasis of HCC: predictors, early detection and experimental antiangiogenic therapy. World J Gastroenterol 2000; 6: 61-65.
29. Lee J, Park SY, Lee EK, et al. Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clin Cancer Res 2006; 12: 6351-6358.
30. Chung TW, Lee YC and Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J 2004; 18: 1123-1125.
31. Simon C, Goepfert H and Boyd D. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMAinduced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res 1998; 58: 1135-1139.